U.S. markets closed

Amneal Pharmaceuticals, Inc. (AMRX)

NYSE - NYSE Delayed Price. Currency in USD
4.2700-0.0200 (-0.47%)
At close: 04:00PM EDT
4.2600 -0.01 (-0.23%)
After hours: 07:51PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close4.2900
Bid4.0000 x 1300
Ask4.5300 x 1000
Day's Range4.1600 - 4.3650
52 Week Range1.2400 - 4.7400
Avg. Volume1,179,776
Market Cap1.308B
Beta (5Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateNov 02, 2023 - Nov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
14% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AMRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amneal Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/20/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • Simply Wall St.

    Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) institutional investors lost 11% over the past week but have profited from longer-term gains

    Key Insights Significantly high institutional ownership implies Amneal Pharmaceuticals' stock price is sensitive to...

  • Business Wire

    Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection

    BRIDGEWATER, N.J., September 06, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced it has received Abbreviated New Drug Application ("ANDA") approval from the U.S. Food and Drug Administration ("FDA") for calcium gluconate in sodium chloride injection, 1000 mg/50 mL and 2000 mg/100 mL. This injectable product is currently on the U.S. FDA shortage product list.

  • Business Wire

    Amneal Receives First Product Approval in China

    BRIDGEWATER, N.J., September 06, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced it has received its first product approval in China. Sevelamer carbonate was approved and is expected to launch shortly. In addition, the Company expects to launch oseltamivir phosphate in China this year as well, upon approval. In total, Amneal has 6 products pending review in China with more product registrations planned over time. Since 2019, the Company has collaborate